

Treatment of 6 COVID-19 Patients with Convalescent Plasma

Can Jin¹; Juan Gu, PhD²; Youshu Yuan³; Qinying Long³; Qi Zhang³; Hourong Zhou, MD⁴; Weidong Wu, MD⁵; Wei Zhang, MD^{1*}

¹Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China. (Email: jincancan0618@163.com)

²Department of Clinical Pharmacy, Affiliated Hospital of Zunyi Medical University, Zunyi, Guizhou, 563000, China. (Email: juanjuan20112012@163.com)

³Guizhou University School of Medicine, Guiyang, Guizhou, 550025, China. (Youshu Yuan, Email: 2271048509@qq.com; Qinying Long, Email: 2681235339@qq.com; Qi Zhang, Email: 986317439@qq.com)

⁴Department of General Medicine, Guizhou Provincial People's Hospital, Guiyang, Guizhou, 550025, China. (Hourong, Zhou, Email: 402843243@qq.com)

⁵Guizhou Normal College, Guiyang, Guizhou, 550025, China. (Weidong Wu, Email: weidw@163.com)

*Corresponding authors

Wei Zhang, MD: Institute: Department of Critical Care Medicine, Affiliated Hospital of Zunyi Medical University; Address: 149 Dalian Road, Zunyi, Guizhou, 563000, China. Tel: +8618982262419; Fax: +86085128879936; E-mail: zhangwei_hxicu@163.com

ABSTRACT

Objective To describe the efficacy of convalescent plasma transfusion for COVID-19 patients.

Methods Through the review of the electronic medical records of Guizhou Jiangjunshan Hospital, clinical data of 6 patients were obtained. Three of the patients used convalescent plasma therapy for the first treatment, while the other three patients were used during in the recurrence. The efficacy of convalescent plasma depends on the relief of symptoms, changes in laboratory indicators and chest imaging abnormalities.

Results The PaO₂ / FiO₂ and lymphocyte count of patients 1, 2 and 3 treated with convalescent plasma treatment for the first treatment period were changed from abnormal to normal. The levels of inflammation markers CRP and IL-6 of the patients decreased significantly. Chest imaging examination showed that the lung lesions gradually subsided. The relapsed patients (No. 4 and No. 6), after using convalescent plasma therapy, turned negative on two consecutive throat swab tests on Day 24 and Day 3, respectively. The basic condition of patient 4 with in the recurrence was too poor, and only one round of convalescent plasma transfusion was performed, so the laryngeal swab test paper has been consistently positive so far.

Conclusions Six patients with COVID-19 were treated with antivirals and systemic corticosteroids combined with appropriate rounds of convalescent plasma therapy, and their clinical conditions were effectively improved.

Keywords

SARS-CoV-2; COVID-19; convalescent plasma therapy; Treatment

Introduction

In December 2019, Wuhan, China, became the center of pneumonia outbreaks caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)[1]. The World Health Organization (WHO) subsequently named it coronavirus disease 2019 (COVID-19) and declared it a pandemic. As of May 1, 2020, the latest data released by the World Health Organization: Globally, the number of confirmed cases of COVID-19 increased by 84,771 cases from the previous day, with a total of 3,175,207 cases; deaths increased by 6,403 cases from the previous day, and the total number of deaths 224172. To date, except for supportive care, there is no specific therapeutic agents or vaccines have been proven effective for COVID-19. Several anti-viral agents seem to be clinical beneficial, but their efficacy is far from satisfactory and the mechanism is not cleared [2-4]. Recent studies are exploring the use of antivirals in the treatment of COVID-19 and conducting clinical trials to evaluate their effectiveness. These experimental therapies include Favipiravir, Lopinavir-ritonavir, Remdesivir, Chloroquine/ Hydroxychloroquine, IL-6 inhibitors and convalescent plasma [5].

Convalescent plasma refers to plasma separated from an individual after the infection has subsided and the antibody has developed. Transfusion of convalescent plasma may reduce the clinical infection or the clinical severity of patients who have recently been infected with pathogens [4]. Convalescent plasma therapy has a favorable effect on viral load, serum cytokine response and mortality. Historically, there have been many successful applications of convalescent plasma therapy in aspost-exposure prophylaxis (e.g. rabies, hepatitis, measles, mumps, polio) and various infectious diseases treated after infection (e.g. Ebola virus, Middle East respiratory syndrome, SARS-CoV, Argentine hemorrhagic fever, H5N1 avian influenza, and H1N1 influenza)[4-11]. In the latest research report by Shen et al., Preliminary results of 5 critically ill patients with COVID-19 and Acute Respiratory Distress Syndrome (ARDS) treated with plasma from recovered

individuals showed that about 1 week after plasma transfusion, the clinical status of all patients improved, body temperature returned to normal, and Sequential Organ Failure Assessment scores and PaO₂ / FiO₂ ratio (PaO₂ measured in mm Hg and FiO₂ measured as fraction of inspired oxygen) as well as have improved. Within 12 days after the transfusion, the patient's neutralizing antibody titer increased, and the respiratory samples tested for SARS-CoV-2 was negative [12].

These findings suggest the hypothesis that restorative plasma infusion may be beneficial for patients infected with SARS-CoV-2 [13]. However, plasma treatment of COVID-19 is not widely used. As the current number of COVID-19 cases and the number of deaths related to the disease are increasing at an alarming rate, an urgent issue needs to be addressed promptly is that more timely clinical trials to determine the safety and effectiveness of convalescent plasma therapy.

Methods

Patients

We did this study in 6 patients admitted to Guizhou Jiangjunshan Hospital who were laboratory confirmed COVID-19 cases by using throat swab SARS-CoV-2 real-time PCR and had undergone convalescent plasma transfusion. Our inclusion criteria were: (1) patients with positive laryngeal swab; (2) difficult to turn negative RT-PCR of COVID-19 infections and severe disease developed rapidly; (3) recurrent patients (patients whose throat swab become negative and then have a positive result) and worsening symptoms after empirically treated with antivirals. The enrolled patients were not allergic to plasma contents; negative for HBV, HCV, HIV; and not mixed with other bacterial infections. The patient continued to use antivirals while using convalescent plasma therapy. This study was approved by the Biomedical Ethics Committee of Affiliated Hospital of Zunyi Medical University. We have obtained written informed consent from each participant. This study was registered at the Chinese Clinical Trial Register (CCTR number: ChiCTR2000033056, registered 19 May 2020). URL: <http://www.chictr.org.cn/edit.aspx?pid=53859&htm=4>.

Clinical information

The clinical data of 6 patients was acquired from a review of the hospital electronic medical record and included the following information: Epidemiology, latency, symptoms, and treatment data. The baseline characteristics of Enrolled patients were shown in Table 1. The indicators before and after convalescent plasma transfusion, including clinical data PAO₂ / FIO₂; laboratory data, including lymphocyte count, C-reactive protein (CRP) and IL-6; changes in complications and the time for the laryngeal swab to change from positive to negative.

Donors and convalescent plasma transfusion

Convalescent plasma was collected from 6 patients who had recovered from COVID-19 and their written informed consent was obtained. The donors have been asymptomatic for at least 3 weeks, negative for SARS-CoV-2 nucleic acid for consecutive two RT-PCR tests, need to be seronegative for anti-HBV, HCV and HIV, with a serum SARS-CoV-2 specific ELISA antibody titer greater than 1: 1000 and a neutralizing antibody titer higher than 40. Following donation, according to the New Coronavirus Pneumonia Convalescent Plasma Therapy Guidance of China (2nd edition)[14], ABO-compatible convalescent plasma was gained from the donors and transfused in the patients on the same day (200ml each time), which helps maintain the natural activity of the plasma. Adverse events and serious adverse events related to convalescent plasma transfusion were evaluated by treatment clinicians.

Results

We included 6 of 146 COVID-19 patients in Guizhou Jiangjunshan Hospital who received convalescent plasma therapy. Among them, 3 were difficult to turn negative RT-PCR of COVID-19 infections and developed rapidly, and 3 were recurrent patients and worsening symptoms after empirically treated with antivirals. One thing needed to be explained was that Guizhou Jiangjunshan Hospital did not directly receive COVID-19 patients from the community. These patients have been treated in other non-designated hospitals for a period of time before transferring to Jiangjunshan Hospital. Therefore, they were at a relatively late

course of the illness when admitted to the hospital. The three patients numbered 1, 2, and 3 were in the treatment period, and their disease severity status were critical or severe critical. They were not improved by the general antiviral therapy, so they were treated with convalescent plasma transfusion. The patients with numbers 4, 5, and 6 are in recurrence, two of them are classified as general, and one is of critical type. Because of previous treatments, their symptoms, blood cell count, coagulation test and biochemical analysis upon admission was mostly normal. But the laryngeal swab tests were still positive for a long time after recurrence, so he was treated with convalescent plasma therapy. No adverse reactions were observed in the six patients during and after the convalescent plasma transfusion.

All patients were infected by contact with patients diagnosed with COVID-19. There were two smokers, and two of the six had no preexisting medical conditions. All 6 patients took various antiviral agents and steroids. Most patients in the treatment group manifested as cough, dizziness, sputum production, dyspnea, fatigue and shortness of breath at the onset of the disease. Other common clinical manifestations included fever, sore throat and myalgia. Even though fever is the most important symptom of COVID-19, it is not obvious in these six patients, and only one experienced fever. The shortest incubation period is 2 days, and the longest is 30 days. Convalescent plasma was administered between 22 and 64 days after admission (Table 1).

Convalescent plasma treatment for the patients with the first treatment period

Patient 1 was admitted to the hospital on February 12. At admission, her oxygen saturation was 85%, a ratio of the partial pressure of oxygen (PO₂) to the fraction of inspired oxygen (FiO₂) of 128 (>300 under normal condition) and she received oxygen therapy through nasal catheter. Chest imaging on February 24th showed multiple ground glass opacities (GGOs) in bilateral lungs. Her condition worsened and she still felt respiratory distress and need oxygen supplement. At this time, plasma therapy has been planned for patients, but it has not yet obtained the patient's ABO-compatible convalescent plasma, and only continues to use antiviral therapy. On March 4th, her symptoms and oxygenation are relatively stable. Repeated chest

imaging examinations suggest that there are still irregular patch density lesions in both lungs. Therefore, the convalescent plasma was given on March 4 and the second cycle on March 5. After the treatment, the values of the inflammatory biomarkers CRP, IL-6 and procalcitonin of the patient decreased. Gradual resolution of pulmonary lesions at 3 days after the plasma treatment. The lymphocyte counts gradually returned to normal from low, but the ratio of monocytes was still high at 10.10-12.40 (normal range, 0-7). Interval between convalescent plasma therapy and laryngeal swab to negative was 5 day (Table 2).

Patient 2 was admitted to the hospital on February 2. He had an increase in C-reactive protein (19.5) and IL-6 (18.1). He was moderately anemic. Chest imaging on March 1 showed no changes in multiple GGOs in the bilateral lungs and worse lesions in the right lower lobe. And combined with fungal infections. During this period, the patient's Throat swab tests had been positive and continued to have moderate anemia. The patient received transfusion of convalescent plasma on March 3, and the second cycle of intervention was given on March 4. Gradual resolution of pulmonary lesions after the plasma treatment. After infusion of convalescent plasma, the patient's CRP, IL-6 and neutrophil ratio gradually decreased from higher abnormal values. The lymphocyte counts gradually increased from a low abnormal value, and the monocyte ratio gradually increased from a low to normal. The time from the convalescent plasma treatment to the negative of the patient's laryngeal swab was 10 days (Table 2).

On February 4, patient 3 was admitted to the hospital. He continued to have a fever ($T_{max} 38.5^{\circ}C$) from February 2 to before convalescent plasma treatment (March 14), and $PaO_2 / FiO_2 < 300$. Chest CT on March 5 showed the presence of GGOs in the upper right lung still. Before the convalescent plasma transfusion, the patient's PaO_2 / FiO_2 was 260, and it rose to 327 a day after this intervention. The patient's body temperature returned to normal from $37.6^{\circ}C$ before plasma transfusion. It took only 2 days from exercised convalescent plasma therapy until the laryngeal swab tests turned negative (Table 2).

Convalescent plasma treatment for the patients with recurrence

The patient with the number 4,5,6 was in a recurrence. Because they had received previous treatment, they

were asymptomatic, and their blood cell count and biochemical analysis were basically normal at admission. Chest CT on Patient 4 showed GGOs around the right lobe lung and patients 3 and 5 was otherwise normal. The time interval from the first admission of three patients diagnosed with COVID-19 to the first negative laryngeal swab tests was 25, 14 and 18 days respectively. The time from the negative of this laryngeal swab to the reappearance of positive test was 13, 47, 37 days. The time between the re-admission of patients 4 and 5 to the hospital and adopted plasma therapy was 3 and 6 days respectively, and they only received one round of convalescent plasma transfusion. Patient 3 received the intervention on the 3rd and 25th days after re-admission. They were still receiving antiviral therapy while receiving convalescent plasma therapy. After 26 days of plasma treatment, patient No. 3 tested negative on pharyngeal test strips. Patient No. 5 only turned negative on the third day after the intervention. they were discharged after several consecutive SARS-CoV-2 pharyngeal swab tests. As of April 27, 2020, it was already the 22nd day after Patient No. 4 was using plasma therapy, and the patient's pharyngeal test paper still showed positive results and continued hospitalization.

Discussion

This descriptive study is based on six cases to explore the efficacy of convalescent plasma therapy on COVID-19. According to the previous experience with convalescent plasma treatment in SARS and severe influenza[15, 16], the production of endogenous IgM and IgG antibodies peaks at two and four weeks after infection. Therefore, in theory, it should be more effective to use convalescent plasma as soon as possible in the early stage of the disease. However, our study is different from previous SARS and influenza cases, the convalescent plasma was used in the late stage of the disease, because the patients admitted to Guizhou Jianjunshan Hospital have been treated elsewhere, from the onset to plasma treatment Systematic treatment. However, other treatments may affect the relationship between convalescent plasma and antibody levels, such as antivirals and steroids[8].

Fortunately, we found that in all 6 cases, convalescent plasma is still clinically beneficia. Patient No. 1 had

already shown a critical condition before the convalescent plasma treatment. While waiting for the convalescent plasma, continued use the treatment of antivirals and steroids, which really stabilized the disease condition, so we cannot deny the efficacy of antivirals and steroids. There has been much debate about the use of steroids, and it has not been used as a routine treatment from the beginning. Evidence from SARS shows that corticosteroids cannot reduce mortality, but delay virus clearance[17]. In fact, systemic corticosteroids may have the effect of reducing excessive lung damage caused by inflammation[18]. The previous condition of the six patients rapidly deteriorated to ARDS, so they were given intravenous methylprednisolone before convalescent plasma therapy. After patient No. 1 was given steroid therapy before the convalescent plasma, $\text{PaO}_2 / \text{FiO}_2$ had a rapid improvement (from 128 to 247), although it did not return to normal indicators. After the convalescent plasma treatment, $\text{PaO}_2 / \text{FiO}_2$ increased to 335. The $\text{PaO}_2 / \text{FiO}_2$ and lymphocyte count of patients 1, 2 and 3 treated with convalescent plasma treatment for the first treatment period were close to normal. The levels of inflammation markers CRP and IL-6 of the patients decreased significantly. Chest imaging examination also showed that the lung lesions gradually subsided. The autopsy report of COVID-19 is very similar to SARS and MERS-CoV infections: diffuse alveolar injury, exudate and inflammation[19]. And part of the reason for ARDS is the cytokine storm and the host's immune response[20]. Therefore, anti-SARS-CoV-2 IgM and IgG in the convalescent plasma treatment can not only directly neutralize the virus, but also anti-inflammatory components can accelerate the clearance of infected cells to prevent cytokine storms.

It is not surprising to notice that for patients with recurrence, the minimum time for viral clearance with throat swab for two consecutive tests after the treatment of convalescent is 2 days and the maximum time is 24 days. However, patient 5 has had a positive laryngeal swab test since this intervention (2020.4.5) until today (2020.5.20). First, the possible reason is that the patient's basic condition and immune system have been poor, suffering from: high blood pressure, hyperlipidemia, type 2 diabetes, and have undergone various operations (cholecystectomy, hysterectomy, tonsillectomy). Before infusion of plasma during recovery

period, the IgM of this patient was 0.8 g/L, IgG was 5.56 g/L (both lower than normal), and CD4⁺/CD8⁺ was 4.34. Secondly, anti-SARS-CoV-2 IgM and IgG in the convalescent plasma treatment are insufficient to neutralize the virus in the body. In addition, the patient only received one round of convalescent plasma therapy, and then he has been treated with antivirals and steroids. Therefore, we speculate that if one round of convalescent plasma transfusion is given to this patient, the effect of this intervention may be enhanced, so that the laryngeal swab test will become negative more quickly. And there is a report saying that antibodies in the plasma in the recovery period can maintain a higher antibody titer and increase the host's immune response until the virus infection is cleared so as to provide full protection[5].

This study was limited by the small sample size. However, we included patients who were treated with plasma therapy for the first time and patients who relapsed. Our study population was typical of patients in Guizhou Province. Our research shows that the transfusion of convalescent plasma is another option for the treatment of COVID-19, especially when used with antivirals and systemic corticosteroids, and it did not cause any serious adverse effects. As more and more patients with COVID-19 have recovered from the infection, the convalescent plasma therapy will be encouraged and active voluntary donation of convalescent plasma will be greatly appreciated.

Conclusions

Six patients with COVID-19 were treated with antivirals and systemic corticosteroids combined with appropriate rounds of convalescent plasma therapy, and their clinical conditions were effectively improved.

Declaration

Ethics approval and consent to participate

Written consent from the patients or their relatives was signed, although entirely anonymized data from which the individual cannot be identified. This study was approved by the Biomedical Ethics Committee of Affiliated Hospital of Zunyi Medical University.

Consent to publish

Although entirely anonymized data and images from which the individual cannot be identified in this paper, we have access to the consent form from all participants. All authors have read and approved the manuscript version, and agree to submit for consideration for publication in the journal. We confirm that we have read the Journal's position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.

Availability of data and materials

We stated that all the data and materials were true and available in the study.

Author's comments

I had full access to all of the data in this study and I take complete responsibility for the integrity of the data and the accuracy of the data analysis.

Disclosure

All authors have any conflict of interest to disclose.

Competing interests

All authors declared that there are no conflicts interests involved in the article.

Funding

This study was supported by Science and Technology Support Plan of Guizhou Province in 2019 (Qian Ke He Support [2019] 2834) and Science and Technology Plan of Guizhou Province in 2020 (Qian Ke He Fundamental [2020] 1Z061).

Authors' contributions

Wei Zhang had full access to all data in the present study and accepts responsibility for data management and accuracy of the data analyses. Study concept and design: Wei Zhang, and Weidong Wu. Acquisition and interpretation of data: Can Jin, Juan Gu, and Youshu Yuan. Drafting of the manuscript: Can Jin and Wei Zhang. Critical revision of the manuscript for important intellectual content: Weidong Wu and Wei Zhang. Administrative, technical, or material support: Qinying Long, Qi Zhang, and Hourong Zhou. Study

supervision: Wei Zhang and Weidong Wu. All authors agree to submission of the final version of this manuscript. Wei Zhang is the study guarantor.

Acknowledgements

The authors thank Ping Lu, Min Yao, Yang Hong, Jinhua Wu, et.al. gave us selfish helps on the process of database construction of COVID-19 in this study.

REFERENCES:

1. Phelan AL, Katz R, Gostin LO: The Novel Coronavirus Originating in Wuhan, China: Challenges for Global Health Governance. *Jama* 2020.
2. Lu H: Drug treatment options for the 2019-new coronavirus (2019-nCoV). *Biosci Trends* 2020, 14(1):69-71.
3. Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention. *Jama* 2020.
4. Kalil AC: Treating COVID-19-Off-Label Drug Use, Compassionate Use, and Randomized Clinical Trials During Pandemics. *Jama* 2020.
5. Chen L, Xiong J, Bao L, Shi Y: Convalescent plasma as a potential therapy for COVID-19. *Lancet Infect Dis* 2020, 20(4):398-400.
6. Casadevall A, Dadachova E, Pirofski LA: Passive antibody therapy for infectious diseases. *Nat Rev Microbiol* 2004, 2(9):695-703.
7. Casadevall A, Pirofski LA: The convalescent sera option for containing COVID-19. *J Clin Invest* 2020, 130(4):1545-1548.
8. Cheng Y, Wong R, Soo YO, Wong WS, Lee CK, Ng MH, Chan P, Wong KC, Leung CB, Cheng G: Use of convalescent plasma therapy in SARS patients in Hong Kong. *Eur J Clin Microbiol Infect Dis* 2005, 24(1):44-46.
9. Hung IF, To KK, Lee CK, Lee KL, Chan K, Yan WW, Liu R, Watt CL, Chan WM, Lai KY *et al*: Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection. *Clin Infect Dis* 2011, 52(4):447-456.
10. Kraft CS, Hewlett AL, Koepsell S, Winkler AM, Kratochvil CJ, Larson L, Varkey JB, Mehta AK, Lyon GM, 3rd, Friedman-Moraco RJ *et al*: The Use of TKM-100802 and Convalescent Plasma in 2 Patients With Ebola Virus Disease in the United States. *Clin Infect Dis* 2015, 61(4):496-502.

Original Research

11. Zhou B, Zhong N, Guan Y: Treatment with convalescent plasma for influenza A (H5N1) infection. *N Engl J Med* 2007, 357(14):1450-1451.
12. Shen C, Wang Z, Zhao F, Yang Y, Li J, Yuan J, Wang F, Li D, Yang M, Xing L *et al*: Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. *Jama* 2020, 323(16):1582-1589.
13. Ye M, Fu D, Ren Y, Wang F, Wang D, Zhang F, Xia X, Lv T: Treatment with convalescent plasma for COVID-19 patients in Wuhan, China. *J Med Virol* 2020.
14. Jacobsen KH: Will COVID-19 generate global preparedness? *Lancet* 2020, 395(10229):1013-1014.
15. Luke TC, Kilbane EM, Jackson JL, Hoffman SL: Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment? *Ann Intern Med* 2006, 145(8):599-609.
16. Soo YO, Cheng Y, Wong R, Hui DS, Lee CK, Tsang KK, Ng MH, Chan P, Cheng G, Sung JJ: Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients. *Clin Microbiol Infect* 2004, 10(7):676-678.
17. Hui DS: Systemic Corticosteroid Therapy May Delay Viral Clearance in Patients with Middle East Respiratory Syndrome Coronavirus Infection. *American journal of respiratory and critical care medicine* 2018, 197(6):700-701.
18. Hanley B, Lucas SB, Youd E, Swift B, Osborn M: Autopsy in suspected COVID-19 cases. *J Clin Pathol* 2020, 73(5):239-242.
19. Russell CD, Millar JE, Baillie JK: Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. *Lancet* 2020, 395(10223):473-475.
20. Ahn JY, Sohn Y, Lee SH, Cho Y, Hyun JH, Baek YJ, Jeong SJ, Kim JH, Ku NS, Yeom JS *et al*: Use of Convalescent Plasma Therapy in Two COVID-19 Patients with Acute Respiratory Distress Syndrome in Korea. *J Korean Med Sci* 2020, 35(14):e149.

Original Research

Patient						
Serial number	1	2	3	4	5	6
Sex	Female	Male	Male	Male	Female	Male
Age, y	64	75	64	51	53	56
Blood type	B	A	O	O	A	A
Smoking	No	Yes	Yes	No	No	No
Disease severity status	Severe Critical	Severe Critical	Critical	General	General	Critical
Cluster disease	Yes	Yes	Yes	Yes	Yes	Yes
Coexisting chronic diseases	Coronary disease;	Cardiac insufficiency			Hypertension; hyperlipidemia;	
	diabetes mellitus;	(grade □);			diabetes mellitus,	
	cerebral infarction	postoperative esophageal cancer	None	None	cholecystectomy; hysterectomy; tonsillectomy	Hypertension; coronary heart disease; cerebral hemorrhage; bilateral renal artery stenosis
Symptoms						
Fever	No	No	Yes	No	No	No
Cough	Yes	Yes	Yes	No	Yes	No
Dizziness	Yes	Yes	No	No	No	No
Sputum production	Yes	Yes	Yes	No	Yes	No
Sore throat	Yes	No	No	No	Yes	No
Dyspnea	Yes	Yes	Yes	No	No	No
Fatigue	Yes	Yes	No	Yes	No	No
Shortness of breath	Yes	Yes	No	No	No	No
Myalgia	Yes	No	No	No	No	No
Disease presentation and course						
Estimated incubation period, d	30	2	8	2	6	13
Interval between symptom onset and treatment, d	31	16	10	6	18	17
Interval between admission and plasma transfusion, d	22	30	38	38	63	64
Complications prior to plasma transfusion		Bacterial pneumonia;				
		fungal pneumonia;				
	Bacterial pneumonia;	severe ARDS;	Bacterial pneumonia;	Bacterial pneumonia;		
	severe ARDS;	moderate anemia ;	severe ARDS	liver damage	None	None
	moderate anemia	myocardial damage				
Recurrence	No	No	No	Yes	Yes	Yes
Treatments	Antivirals,	Antivirals,	Antivirals,	Antivirals,	Antivirals,	Antivirals, Steroids

Original Research

Table 1. Clinical characteristics of the 6 participants who received convalescent plasma

Table 2. Comparison of clinical Indexes and laboratory results before and after convalescent plasma transfusion

Patient	1	2	3	4	5	6
PaO ₂ /FiO ₂ (normal range, 400-500)						
Before transfusion	247	368	260	> 300	> 300	> 300
Post transfusion	335	326	327	> 300	> 300	> 300
Lymphocyte count, % (normal range, 20-40)						
Before transfusion	14.5	2.8	N	N	34.1	25.2
Post transfusion	32	12.1	N	N	43.1	41.5
Monocyte ratio, % (normal range, 3-8)						
Before transfusion	12	1	N	8.7	N	9.5
Post transfusion	12.4	6.7	N	6.8	7.7	8.6
CRP, mg/L (normal range, <8)						
Before transfusion	319	76	19.5	N	6	2.75
Post transfusion	46	16	9	N	1.39	N
IL-6, pg/ml (normal range, 0-7)						
Before transfusion	56.51	14.44	18.1	1.5	5.1	< 1.5
Post transfusion	11.2	9.36	9.26	N	4.2	N
Chest CT presentation						
	irregular patch lesions	extensive lung lesions	GGOs in the upper right lung	GGOs around the right lobe lung	normal	normal
Before transfusion						
Post transfusion	slightly absorbed	slightly absorbed	slightly absorbed	slightly absorbed	normal	normal
Interval between convalescent plasma therapy and laryngeal swab to negative, d	5	10	2	24	Still positive	3
Length of hospital stay, d	59	54	49	63	Remains hospitalized	64

Figure 1. CONSORT Flow Diagram of This Study

